
SeaSpine Holdings Corporation SPNE
Quarterly report 2022-Q3
added 11-03-2022
SeaSpine Holdings Corporation Book Value 2011-2026 | SPNE
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value SeaSpine Holdings Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 312 M | 172 M | 110 M | 142 M | 106 M | 111 M | 147 M | 91.3 M | 111 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 312 M | 91.3 M | 145 M |
Quarterly Book Value SeaSpine Holdings Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 274 M | - | 297 M | 312 M | 327 M | 341 M | 159 M | 172 M | 172 M | 172 M | 172 M | 110 M | 110 M | 110 M | 110 M | 142 M | 142 M | 142 M | 142 M | 106 M | 106 M | 106 M | 106 M | 111 M | 111 M | 111 M | 111 M | 147 M | 147 M | 147 M | 147 M | 91.3 M | 91.3 M | 91.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 341 M | 91.3 M | 156 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
3.85 B | $ 187.53 | 0.54 % | $ 14 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 291.34 | -1.6 % | $ 8.22 B | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 39.12 | -0.91 % | $ 5.83 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.48 | -1.34 % | $ 1.69 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.61 | 3.18 % | $ 38 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.55 | 0.85 % | $ 133 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 64.77 | 0.26 % | $ 95.9 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 10.46 | - | $ 296 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
43.2 M | $ 25.88 | 0.66 % | $ 219 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 17.49 | -2.04 % | $ 410 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 93.94 | -0.62 % | $ 12.7 B | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.92 | -1.03 % | $ 1.17 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 5.04 | 3.6 % | $ 1.07 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Inogen
INGN
|
192 M | $ 6.2 | - | $ 165 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.02 | -1.92 % | $ 17.3 M | ||
|
LENSAR
LNSR
|
-12.2 M | $ 6.22 | -0.56 % | $ 74.4 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
111 M | $ 10.76 | -2.09 % | $ 385 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 56.25 | -0.72 % | $ 1.65 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 39.15 | -0.79 % | $ 1.22 B | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 65.23 | 0.14 % | $ 3.56 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 87.02 | -0.9 % | $ 3.02 B | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.8 | 0.16 % | $ 123 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 77.81 | -0.49 % | $ 45.5 B | ||
|
Penumbra
PEN
|
1.43 B | $ 332.81 | 0.12 % | $ 13 B |